vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($270.7M vs $151.7M, roughly 1.8× Nutex Health, Inc.). BALCHEM CORP runs the higher net margin — 14.9% vs 7.8%, a 7.1% gap on every dollar of revenue. On growth, BALCHEM CORP posted the faster year-over-year revenue change (8.1% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $33.8M). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 7.5%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
BCPC vs NUTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.7M | $151.7M |
| Net Profit | $40.3M | $11.8M |
| Gross Margin | — | 30.4% |
| Operating Margin | 20.5% | 20.4% |
| Net Margin | 14.9% | 7.8% |
| Revenue YoY | 8.1% | -41.1% |
| Net Profit YoY | 8.7% | -80.8% |
| EPS (diluted) | $1.25 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | $151.7M | ||
| Q3 25 | $267.6M | $267.8M | ||
| Q2 25 | $255.5M | $244.0M | ||
| Q1 25 | $250.5M | $211.8M | ||
| Q4 24 | $240.0M | $257.6M | ||
| Q3 24 | $239.9M | $78.8M | ||
| Q2 24 | $234.1M | $76.1M |
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | $11.8M | ||
| Q3 25 | $40.3M | $55.4M | ||
| Q2 25 | $38.3M | $-17.7M | ||
| Q1 25 | $37.1M | $21.2M | ||
| Q4 24 | $33.6M | $61.6M | ||
| Q3 24 | $33.8M | $-8.8M | ||
| Q2 24 | $32.1M | $-364.0K |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | 30.4% | ||
| Q3 25 | 35.7% | 57.8% | ||
| Q2 25 | 36.4% | 51.2% | ||
| Q1 25 | 35.2% | 55.9% | ||
| Q4 24 | 36.0% | 55.0% | ||
| Q3 24 | 35.6% | 27.8% | ||
| Q2 24 | 35.5% | 29.7% |
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | 20.4% | ||
| Q3 25 | 20.4% | 48.7% | ||
| Q2 25 | 20.1% | 13.8% | ||
| Q1 25 | 20.4% | 38.1% | ||
| Q4 24 | 19.8% | 44.4% | ||
| Q3 24 | 20.0% | 12.3% | ||
| Q2 24 | 19.6% | 7.0% |
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | 7.8% | ||
| Q3 25 | 15.1% | 20.7% | ||
| Q2 25 | 15.0% | -7.3% | ||
| Q1 25 | 14.8% | 10.0% | ||
| Q4 24 | 14.0% | 23.9% | ||
| Q3 24 | 14.1% | -11.2% | ||
| Q2 24 | 13.7% | -0.5% |
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | $2.34 | ||
| Q3 25 | $1.24 | $7.76 | ||
| Q2 25 | $1.17 | $-2.95 | ||
| Q1 25 | $1.13 | $3.33 | ||
| Q4 24 | $1.03 | $11.56 | ||
| Q3 24 | $1.03 | $-1.72 | ||
| Q2 24 | $0.98 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $72.9M | $185.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $329.4M |
| Total Assets | $1.7B | $918.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | $185.6M | ||
| Q3 25 | $65.1M | $166.0M | ||
| Q2 25 | $65.4M | $96.7M | ||
| Q1 25 | $49.9M | $84.7M | ||
| Q4 24 | $49.5M | $40.6M | ||
| Q3 24 | $73.7M | $46.9M | ||
| Q2 24 | $63.7M | $40.8M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $329.4M | ||
| Q3 25 | $1.3B | $317.2M | ||
| Q2 25 | $1.3B | $235.3M | ||
| Q1 25 | $1.2B | $176.9M | ||
| Q4 24 | $1.1B | $132.4M | ||
| Q3 24 | $1.2B | $60.4M | ||
| Q2 24 | $1.1B | $62.7M |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $918.5M | ||
| Q3 25 | $1.7B | $964.5M | ||
| Q2 25 | $1.7B | $841.0M | ||
| Q1 25 | $1.6B | $761.9M | ||
| Q4 24 | $1.6B | $655.3M | ||
| Q3 24 | $1.6B | $438.5M | ||
| Q2 24 | $1.6B | $422.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $40.1M | $70.4M |
| Free Cash FlowOCF − Capex | $33.8M | $69.0M |
| FCF MarginFCF / Revenue | 12.5% | 45.5% |
| Capex IntensityCapex / Revenue | 2.3% | 0.9% |
| Cash ConversionOCF / Net Profit | 0.99× | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | — | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | $70.4M | ||
| Q3 25 | $65.6M | $99.5M | ||
| Q2 25 | $47.3M | $27.3M | ||
| Q1 25 | $36.5M | $51.0M | ||
| Q4 24 | $52.3M | $54.0K | ||
| Q3 24 | $51.3M | $6.8M | ||
| Q2 24 | $45.0M | $13.3M |
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | $69.0M | ||
| Q3 25 | — | $99.2M | ||
| Q2 25 | — | $26.5M | ||
| Q1 25 | — | $50.9M | ||
| Q4 24 | — | $-341.0K | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | — | $12.7M |
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | 45.5% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | — | 24.0% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | — | 16.7% |
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | 0.7% |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | 5.95× | ||
| Q3 25 | 1.63× | 1.80× | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | 2.40× | ||
| Q4 24 | 1.56× | 0.00× | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
Segment breakdown not available.
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
